Third-Trimester HIV Viremia Treated With Long-Acting Cabotegravir and Rilpivirine: A Case Report

Abstract

We report the first case to quantitatively demonstrate a rapid and substantial viral load reduction using long-acting cabotegravir and rilpivirine in the third trimester of pregnancy. This case underscores the challenges some pregnant individuals face with daily oral antiretroviral therapy and the potential role of long-acting injectables in select scenarios.